A5014663441- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Vascular Anomalies and Treatments
- Hepatitis C virus research
- SARS-CoV-2 and COVID-19 Research
- Cannabis and Cannabinoid Research
- Thyroid Disorders and Treatments
- Tracheal and airway disorders
- Growth Hormone and Insulin-like Growth Factors
- Long-Term Effects of COVID-19
- Cancer-related Molecular Pathways
- SARS-CoV-2 detection and testing
- Neurotransmitter Receptor Influence on Behavior
- COVID-19 Clinical Research Studies
- Peptidase Inhibition and Analysis
- Pulmonary Hypertension Research and Treatments
- Biosensors and Analytical Detection
- Cytomegalovirus and herpesvirus research
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Estrogen and related hormone effects
- Cancer Research and Treatments
Centro de Investigaciones Biológicas Margarita Salas
2017-2023
Universidad de Alcalá
2000-2023
Centre for Biomedical Network Research on Rare Diseases
2017-2023
Consejo Superior de Investigaciones Científicas
2009-2023
IrsiCaixa
2007-2022
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2007-2022
Instituto Ramón y Cajal de Investigación Sanitaria
2021-2022
Instituto Cajal
2021-2022
Centro de Investigación Biomédica en Red
2017-2021
Universidad Autónoma de Madrid
2009-2021
Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the response to combination therapy. Widespread transmission of variants has disturbing potential limiting future therapy options and affecting efficacy postexposure prophylaxis.We determined baseline rate drug resistance in 2208 therapy-naive patients recently chronically infected HIV-1 from 19 European countries during 1996-2002.In Europe, 10 antiretroviral-naive carried viruses > or = drug-resistance...
No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious outpatients COVID-19.Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020. Patients recently diagnosed <5-day of symptom onset were assigned receive HCQ (800 mg on day 1 followed by 400 once daily 6 days) or usual care. Outcomes reduction viral load nasopharyngeal...
BackgroundCurrent strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxychloroquine has been proposed as a postexposure therapy prevent disease 2019 (Covid-19), but definitive evidence is lacking.MethodsWe conducted an open-label, cluster-randomized trial involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)–confirmed Covid-19 in Catalonia, Spain. We randomly assigned...
Abstract The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics antibody responses and their association with disease severity. Between March May 2020, prospective KING study enrolled 72 COVID-19+ participants grouped according to infection was diagnosed by serological virological tests. Plasma were assessed against replicative virus pseudoviral particles. Multiple regression...
To determine whether HIV-1 genotyping and expert advice add additional short-term virologic benefit in guiding antiretroviral changes HIV+ drug-experienced patients.A two factorial (genotyping advice), randomized, open label, multi-center trial. The patients were stratified according to the number of treatment failures.HIV-1 infected on stable therapy who presented virological failure included into study. Genotypic testing was performed by using TrueGene HIV Genotyping kit results...
Objective: To determine the prevalence of genotypic resistance to nucleoside analogues (NA) in a large group HIV-infected individuals Spain, some whom had no previous treatment with antiretroviral drugs (antiretroviral-naive) and such experience (antiretroviral-experienced). Setting: Cross-sectional study outpatient clinics three reference hospitals for HIV/AIDS located Barcelona, Madrid Seville, Spain. Patients methods: Primary mutant genotypes were examined plasma HIV RNA collected from...
The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and Israel with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection. overall prevalence TDR was 8.4% (225 2687 patients; 95% confidence interval [CI], 7.4%-9.5%), nucleoside reverse-transcriptase inhibitor (NRTI) 4.7% (125 CI, 3.9%-5.5%), nonucleoside (NNRTI) 2.3% (62 1.8%-2.9%), protease...
Objective To investigate the virological and immunological impact of a structured treatment interruption (STI) in cohort HIV-1 chronically infected patients with further long-lasting effective virus suppression. Methods Twelve adults who had maintained viral suppression (< 20 copies/ml) for more than 2 years, as well CD4 : CD8 ratio > 1 median time 22 months, were included study. Participants interrupted their antiretroviral during maximum period 30 days or until load rebound 3000 copies/ml...
Seven AIDS patients who were receiving suppressive therapy for previously diagnosed cytomegalovirus (CMV) retinitis offered treatment with protease inhibitors (PIs). Secondary prophylaxis CMV was discontinued after 3 months of PIs if had >150 CD4 cells/mm3 and a human immunodeficiency virus (HIV) load <200 copies/mL they negative as determined by qualitative polymerase chain reaction (PCR). Ophthalmologic exams done periodically. After median follow-up 9 (range, 9-12), no new episodes...
The banning of mass-gathering indoor events to prevent SARS-CoV-2 spread has had an important effect on local economies. Despite growing evidence the suitability antigen-detecting rapid diagnostic tests (Ag-RDT) for mass screening at event entry, this strategy not been assessed under controlled conditions. We aimed assess effectiveness a prevention during live concert.
Significance We show here that binding of the thyroid hormone triiodothyronine to receptors (TRs) antagonizes TGF-β/SMAD (mothers against decapentaplegic)-dependent transcription. Transcriptionally inactive TR mutants do not bind coactivators retained most capacity suppressing transactivation by TGF-β/SMAD, whereas selective mutations in DNA domain abolished this action. TGF-β is a major profibrogenic cytokine, and through transcriptional mechanism, hormone-bound TRs act as an endogenous...
Seventy-seven subjects infected with human immunodeficiency virus were randomized to switch from protease inhibitor (PI) therapy nevirapine (group A; n = 26) or efavirenz B; 25) continue PI C; 26). At month 12, viral suppression had been maintained in 96% of patients group A, 92% B, and C. A significant increase the CD4+ level was observed all 3 groups. In lipid profiles improved, whereas levels γ-glutamiltransferase alanine aminotransferase significantly increased; 1 subject interrupted...
Background: Simpler and less toxic antiretroviral strategies are needed to maximize treatment compliance without sacrificing potency, at least for drug-experienced HIV-infected patients currently on regimens containing protease inhibitors (PIs). Small nonrandomized studies have suggested a beneficial role of PI-sparing lipodystrophy. Objectives: To assess the virologic, immunologic, clinical benefit switching PI nevirapine in with HIV-associated lipodystrophy sustained viral suppression...
The effect of Δ 9 ‐tetrahydrocannabinol (THC), the major psycho‐active component marijuana, in human prostate cancer cells PC‐3 was investigated. THC caused apoptosis a dose‐dependent manner. Morphological and biochemical changes induced by shared characteristics an apoptotic phenomenon. First, loss plasma membrane asymmetry determined fluorescent anexin V binding. Second, presence bodies nuclear fragmentation observed DNA staining with 4′,6‐diamino‐2‐phenylindole (DAPI). Third, typical...
In most European countries, HIV drug resistance testing has become a routine clinical tool. However, its practical implementation in context is demanding. The Drug Resistance Panel was established to make recommendations clinicians and virologists on this topic propose quality control measures. panel recommends for the following indications: i) drug-naive patients with acute or recent infection; ii) therapy failure, including suboptimal treatment response, when change considered; iii)...
Background The widespread use of protease inhibitors (PI) has been associated with abnormalities in the lipid profile HIV-1-infected patients. Treatment simplification approaches which PI are replaced by nevirapine (NVP) have shown to improve PI-related toxicity. Objective To assess impact on plasma lipids replacing NVP HIV-1 infected patients lipodystrophy. Methods We studied 34 lipodystrophy who had first be enrolled a prospective, randomized trial continuing current treatment, or NVP....
Objective: To define genotypic and phenotypic resistance patterns following prolonged therapy with the protease inhibitor ritonavir (ABT-538). Design: Seven HIV-1-infected patients, all but one previously treated dideoxynucleoside analogues (zidovudine, didanosine, zalcitabine), were for 1 year ritonavir. Methods: Direct solid-phase sequencing of gene starting from plasma derived viral RNA followed by comparison to drug data. Results: The most frequent amino-acid substitutions occurring upon...
Objective: To determine the rate of virological rebound and factors associated with among patients on highly active antiretroviral therapy (HAART) previously undetectable levels viraemia. Design: An observational cohort study 2444 from EuroSIDA study. Methods: Patients were followed their first viral load under 400 copies/ml to two consecutive loads above copies/ml. Incidence rates calculated using person-years follow-up (PYFU), Cox proportional hazards models used related rebound. Results:...
The genetic barrier, defined as the number of mutations required to overcome drug-selective pressure, is an important factor for development HIV drug resistance. Because high variability between subtypes, particular HIV-1 subtypes could have different barriers resistance substitutions. This study compared barrier using some 2000 sequences (>600 non-B subtype) isolated from anti-retroviral-naive patients in Europe.The was calculated sum transitions (scored 1) and/or transversions (2.5)...
To evaluate protease inhibitor (PI) cross-resistance and reductions in replication capacity conferred by amprenavir-selected mutations.HIV-1IIIB variants derived from passage increasing concentrations of amprenavir were studied, as well 3'Gag/protease recombinants them. These strains progressively accumulated mutations at codons 10, 46, 47, 50 84 the a p1/p6 cleavage site mutation codon 449 Gag. Their susceptibility (IC50) to various PI their corresponding capacities evaluated single-cycle...